Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.38 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 8/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916383 | 0.98 | MGLL (0.40) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL18824035 | 0.94 | FAAH (0.35) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL21100131 | 0.85 | FAAH (0.30) | MGLLFAAH | |
| SCHEMBL20616617 | 0.84 | MGLL (0.38) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL21158066 | 0.82 | MGLL (0.40) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL19704405 | 0.82 | MGLL (0.40) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL20930969 | 0.82 | MGLL (0.40) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL21577840 | 0.81 | FAAH (0.36) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL21577922 | 0.79 | MGLL (0.38) | MGLLFAAHALDH1A1GAAMAPT | |
| SCHEMBL21158545 | 0.79 | MGLL (0.38) | MGLLFAAHALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065340-B2 | Polyoxazoline antibody drug conjugates | SERINA THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190000985-A1 | Polyoxazoline Anitbody Drug Conjugates | SERINA THERAPEUTICS (AL), INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065340-B2 | Polyoxazoline antibody drug conjugates | FCGR2A, FCGR3B, FCGR1A | MGLL 4804/4885FAAH 4375/4885ALDH1A1 3112/4885 |
| US-20190000985-A1 | Polyoxazoline Anitbody Drug Conjugates | CD79B, ANTXR2, FCGR2A | MGLL 4854/4885FAAH 4089/4885ALDH1A1 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.